The molecular etiology of breast cancer: Evidence from biomarkers of risk
โ Scribed by Nilesh W. Gaikwad; Li Yang; Paola Muti; Jane L. Meza; Sandhya Pruthi; James N. Ingle; Eleanor G. Rogan; Ercole L. Cavalieri
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- French
- Weight
- 390 KB
- Volume
- 122
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Estrogens can become endogenous carcinogens via formation of catechol estrogen quinones, which react with DNA to form specific depurinating estrogenโDNA adducts. The mutations resulting from these adducts can lead to cell transformation and the initiation of breast cancer. Estrogen metabolites, conjugates and depurinating DNA adducts in urine samples from 46 healthy control women, 12 highโrisk women and 17 women with breast cancer were analyzed. The estrogen metabolites, conjugates and depurinating DNA adducts were identified and quantified by using ultraperformance liquid chromatography/tandem mass spectrometry. The levels of the ratios of depurinating DNA adducts to their respective estrogen metabolites and conjugates were significantly higher in highโrisk women (p < 0.001) and women with breast cancer (p < 0.001) than in control subjects. The highโrisk and breast cancer groups were not significantly different (p = 0.62). After adjusting for patient characteristics, these ratios were still significantly associated with health status. Thus, the depurinating estrogenโDNA adducts are possible biomarkers for early detection of breast cancer risk and response to preventive treatment. ยฉ 2007 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
## Abstract The use of the fatty acid composition of adipose tissue, erythrocyte membranes, serum and plasma as biological markers of fatty acid intake was recently introduced in epidemiological studies. The biomarkers of fatty acid intake have the advantage of providing quantitative measurement in
## Abstract The oncoprotein encoded by the HERโ2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HERโ2 overexpression with human tumors, its extrace